论文部分内容阅读
80例单用二甲双胍血糖控制不良的2型糖尿病患者,随机分为沙格列汀组(沙格列汀5mg每天1次+二甲双胍500mg每天2次)和阿卡波糖组(阿卡波糖50mg每天3次+二甲双胍500mg每天2次),每组各40例,治疗疗程12周。结果沙格列汀组和阿卡波糖组在治疗后FPG、2h PG水平均较用药前有明显降低(P<0.05),IR降低,细胞功能明显改善(P<0.05)。沙格列汀在控制体重、改善IR方面优于阿卡波糖(P<0.05)。两组均未出现严重低血糖事件。结论与二甲双胍联用,沙格列汀较阿卡波糖更能有效的改善胰岛素抵抗和β细胞功能,且可以降低BMI,患者胃肠道反应小,依从性好。
Eighty patients with type 2 diabetes mellitus with glycemic control alone were randomly assigned to sitagliptin (saxagliptin 5 mg daily plus metformin 500 mg twice daily) and acarbose (acarbose 50 mg 3 times a day + metformin 500mg twice daily), 40 cases in each group, the course of treatment for 12 weeks. Results The levels of FPG and 2h PG in both saxagliptin and acarbose groups were significantly lower than those before treatment (P <0.05), IR was decreased and cell function was significantly improved (P <0.05). Saxagliptin is superior to acarbose in weight control and IR (P <0.05). No severe hypoglycaemia occurred in either group. Conclusion Combined with metformin, saxagliptin is more effective than acarbose in improving insulin resistance and β-cell function, and can reduce the BMI, gastrointestinal reactions in patients with small, good compliance.